Upcoming Opportunities

NIHR Logo

Closing Date: 18 December 2024

NIHR Patient Engagement in Clinical Development Service:

Are you interested in helping to improve health and care research?

Then this is your opportunity to help shape the design of a clinical trial for kidney disease!

The National Institute for Health and Care Research (NIHR) is pleased to share an opportunity for members of the public who have lived or caring experience of IgA nephropathy to be involved in the shaping of a commercial trial.

Who are we looking for?

This opportunity is for up to 8 adults (aged 18 or over) who:

  • Live in the UK
  • Have lived experience, as a patient, or carer of someone, with IgA nephropathy
  • Can access and use an online video calling platform such as Zoom
  • Are happy to discuss their lived experience in a group.

 

What do I have to do?

If you are interested in taking part, please complete the application form link here.

If you are successfully selected for the session, we will invite you to take part in an online group meeting which will last for 2 ½ hours. You will also be asked to read a document about the study before the session, which may take up to 1 hour.

The meeting will be hosted by the NIHR PECD Team, together with the company we are supporting. The session will involve:

  • Hearing about the impact your health condition has on your life
  • The company talking to you about their planned research
  • Sharing your thoughts and feedback on the planned research

 

When will the meeting take place?

A date has not yet been set for this activity, but it is likely to take place in January 2025.

Timings of the session can be flexible, such as evening or late afternoon to allow for working hours and will be agreed in advance by participants and the company representatives.

Frequently Asked Questions (FAQs)

For further information and FAQs please click this link.

NIHR PECD – Charity Partner FAQs

If you are interested in taking part, please visit the link below, or scan the QR code for more information.
 
 
 
 
Skip to content